Decker Retirement Planning Inc. Invests $51,000 in Novo Nordisk A/S (NYSE:NVO)

Decker Retirement Planning Inc. purchased a new position in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 591 shares of the company’s stock, valued at approximately $51,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S in the second quarter worth about $25,000. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S in the third quarter worth about $28,000. Capital Performance Advisors LLP purchased a new position in shares of Novo Nordisk A/S in the third quarter worth about $42,000. Carolina Wealth Advisors LLC purchased a new position in Novo Nordisk A/S during the third quarter worth about $48,000. Finally, M&R Capital Management Inc. raised its stake in Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after purchasing an additional 297 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of analyst reports. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $83.26 on Friday. The company’s 50 day simple moving average is $98.82 and its 200-day simple moving average is $117.93. The company has a market capitalization of $373.61 billion, a price-to-earnings ratio of 26.94, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $80.05 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.